Kaken Pharmaceutical Co., Ltd.
4521.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.35 | -0.60 | -0.56 |
| FCF Yield | 14.99% | 0.31% | 5.08% | 6.82% |
| EV / EBITDA | 5.48 | 6.69 | 8.84 | 5.53 |
| Quality | ||||
| ROIC | 9.21% | 4.98% | 4.27% | 7.82% |
| Gross Margin | 61.96% | 53.49% | 54.20% | 54.68% |
| Cash Conversion Ratio | 2.14 | 0.32 | 1.36 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.81% | -1.78% | -0.89% | -5.20% |
| Free Cash Flow Growth | 6,154.15% | -94.18% | -30.08% | -16.66% |
| Safety | ||||
| Net Debt / EBITDA | -2.28 | -3.72 | -5.93 | -3.49 |
| Interest Coverage | 751.29 | 559.59 | 470.47 | 1,003.76 |
| Efficiency | ||||
| Inventory Turnover | 1.88 | 1.95 | 2.15 | 2.30 |
| Cash Conversion Cycle | 191.36 | 229.98 | 199.36 | 193.03 |